+

WO1997046253A3 - Immunotherapie pour maladie auto-immune - Google Patents

Immunotherapie pour maladie auto-immune Download PDF

Info

Publication number
WO1997046253A3
WO1997046253A3 PCT/US1997/009427 US9709427W WO9746253A3 WO 1997046253 A3 WO1997046253 A3 WO 1997046253A3 US 9709427 W US9709427 W US 9709427W WO 9746253 A3 WO9746253 A3 WO 9746253A3
Authority
WO
WIPO (PCT)
Prior art keywords
delivery
antigen
autoimmune disease
mbp
antigens
Prior art date
Application number
PCT/US1997/009427
Other languages
English (en)
Other versions
WO1997046253A9 (fr
WO1997046253A2 (fr
Inventor
Joel R Haynes
Sudhirdas K Prayaga
Ian A Ramshaw
Original Assignee
Auragen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Auragen Inc filed Critical Auragen Inc
Priority to AU32250/97A priority Critical patent/AU3225097A/en
Publication of WO1997046253A2 publication Critical patent/WO1997046253A2/fr
Publication of WO1997046253A3 publication Critical patent/WO1997046253A3/fr
Publication of WO1997046253A9 publication Critical patent/WO1997046253A9/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

On décrit un traitement de maladies auto-immunes fondé sur l'apport dans la peau d'antigène à l'aide d'un pistolet à gènes, ou l'apport dans la peau d'ADN codant l'antigène. L'apport de collagène ou d'ADN codant le collagène est utile pour traiter l'arthrite rhumatoïde, l'apport de protéine de base de myéline (PBM) ou d'ADN codand le PBM étant quant à lui utile pour traiter la sclérose en plaques. Ces antigènes atténuent les réponses cytotoxiques et favorisent la désensibilisation aux antigènes. A l'aide d'autres antigènes on peut traiter d'autres maladies auto-immunes.
PCT/US1997/009427 1996-06-03 1997-06-03 Immunotherapie pour maladie auto-immune WO1997046253A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU32250/97A AU3225097A (en) 1996-06-03 1997-06-03 Immunotherapy for autoimmune disease

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1910096P 1996-06-03 1996-06-03
US60/019,100 1996-06-03

Publications (3)

Publication Number Publication Date
WO1997046253A2 WO1997046253A2 (fr) 1997-12-11
WO1997046253A3 true WO1997046253A3 (fr) 1998-01-29
WO1997046253A9 WO1997046253A9 (fr) 1998-08-06

Family

ID=21791438

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/009427 WO1997046253A2 (fr) 1996-06-03 1997-06-03 Immunotherapie pour maladie auto-immune

Country Status (2)

Country Link
AU (1) AU3225097A (fr)
WO (1) WO1997046253A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7030098B2 (en) 1999-03-12 2006-04-18 The Board Of Trustees Of The Leland Stanford Junior University DNA vaccination for treatment of autoimmune disease
ATE308244T1 (de) 1999-03-12 2005-11-15 Univ Leland Stanford Junior Dna-impfung zur behandlung von autoimmunerkrankungen
US6884785B2 (en) * 1999-06-17 2005-04-26 The Scripps Research Institute Compositions and methods for the treatment or prevention of autoimmune diabetes
US7544669B2 (en) 2001-11-21 2009-06-09 The Board Of Trustees Of The Leland Stanford Junior University Polynucleotide therapy
SI1569696T1 (sl) 2002-11-21 2010-12-31 Bayhill Therapeutics Inc Postopki in imunsko modulatorna nukleiäśna kislinski sestavki za prepreäśevanje in zdravljenje bolezni
SE535625C2 (sv) 2010-10-28 2012-10-16 Toleranzia Ab Nya kompositioner och förfaranden för behandling av autoimmuna och allergiska sjukdomar
WO2013160865A1 (fr) 2012-04-26 2013-10-31 Toleranzia Ab Protéines hybrides d'immuno-tolérisation pour le traitement de la sclérose en plaques

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992006708A1 (fr) * 1990-10-15 1992-04-30 Brigham And Women's Hospital Traitement de maladies auto-immunes par administration orale d'auto-antigenes
WO1993016724A1 (fr) * 1992-02-28 1993-09-02 Autoimmune, Inc. Suppression de maladies auto-immunes par des antigenes en attente
WO1995007096A1 (fr) * 1993-09-06 1995-03-16 La Trobe University Traitement de maladies auto-immunes
WO1996010039A1 (fr) * 1994-09-27 1996-04-04 Peptide Therapeutics Limited Polypeptides et leur utilisation dans le traitement et la prophylaxie de maladies auto-immunes

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992006708A1 (fr) * 1990-10-15 1992-04-30 Brigham And Women's Hospital Traitement de maladies auto-immunes par administration orale d'auto-antigenes
WO1993016724A1 (fr) * 1992-02-28 1993-09-02 Autoimmune, Inc. Suppression de maladies auto-immunes par des antigenes en attente
WO1995007096A1 (fr) * 1993-09-06 1995-03-16 La Trobe University Traitement de maladies auto-immunes
WO1996010039A1 (fr) * 1994-09-27 1996-04-04 Peptide Therapeutics Limited Polypeptides et leur utilisation dans le traitement et la prophylaxie de maladies auto-immunes

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JOEL R. HAYNES, DENNIS E. MCCABE, WILLIAM F. SWAIN, GEORG WIDERA, JAMES T. FULLER: "Particle-mediated nucleic acid immunization", JOURNAL OF BIOTECHNOLOGY, vol. 44, no. 1-3, 16 January 1996 (1996-01-16), pages 37 - 42, XP002043695 *
S. K. PRAYAGA AND J. R. HAYNES: "Particle-mediated delivery of type II collagen to the epidermis of mice prevents the development of collagen-induced arthritis", FASEB JOURNAL, vol. 10, no. 6, 30 April 1996 (1996-04-30), pages A1025, XP002043694 *
TAMERA M. PERTNER, MICHAEL D. EISENBRAUN, DENNIS MCCABE, SUDHIRDAS K. PRAYAGA, DEBORAH H. FULLER AND JOEL R. HAYNEST: "Gene gun-based nucleic acid immunization: elicitation of humoral and cytotoxic T lymphocyte responses following epidermal delivery of nanogram quantities of DNA", VACCINE, vol. 13, no. 15, 1995, pages 1427 - 1430, XP002043696 *

Also Published As

Publication number Publication date
WO1997046253A2 (fr) 1997-12-11
AU3225097A (en) 1998-01-05

Similar Documents

Publication Publication Date Title
GR3033634T3 (en) Improved treatment of autoimmune diseases by aerosol administration of auto antigens.
AU4612093A (en) Soluble ligands for CD40
AU3040995A (en) Treatment of autoimmune diseases by oral administration of autoantigens
EP0670369A3 (fr) Peptide associée à la mort programmée des cellules humaines et DNA le codant
HUP9904697A2 (hu) Eljárások és készítmények immunmodulációhoz
IL96907A0 (en) Proteins produced by human lymphocytes,a dna sequence coding for said proteins and their pharmaceutical and biological application
WO1998026747A3 (fr) Procedes et compositions de traitement de maladies a base de superantigenes
WO1994011026A3 (fr) Application therapeutique d'anticorps chimeriques et radio-marques contre l'antigene a differentiation restreinte des lymphocytes b humains pour le traitement du lymphome des cellules b
CA2203991A1 (fr) Procedes et dispositifs destines a immuniser un hote d'antigenes associes a une tumeur par l'administration de polynucleotides nus codant des peptides antigeniques associes a une tumeur
HUT74832A (en) Method and compositions for treatment of autoimmune diseases by use of bystander antigen
WO1994029469A3 (fr) Plasmides adequats pour une therapie genique
EP0823438A3 (fr) Protéine du noyau de la mucine humaine: fragments de peptides et anticorps correspondants, et leur utilisation dans des méthodes diagnostiques et thérapeutiques
AU6681794A (en) Nucleotide vector, composition containing such vector and vaccine for immunization against hepatitis
EP1347055A3 (fr) Composés et procédés pour l'immunothérapie et le diagnostic de la tuberculose
WO1998008542A3 (fr) Composes et procedes destines au traitement et au diagnostic d'infections mycobacteriennes
AU7752487A (en) Immunomodulating compositions and their use
WO1997046253A3 (fr) Immunotherapie pour maladie auto-immune
WO1998059040A3 (fr) Sous-unite de telomerase catalytique humaine et son utilisation therapeutique et diagnostique
EP1950226A3 (fr) Un anticorps contre un réceptor pour interleukine - 12 humaine et son utilisation
EP0853486A3 (fr) Utilisation therapeutique de serums d'animaux, en particulier du cheval, pour le traitement du sida, du cancer et d'autres maladies virales et bacteriennes
EP0853486A4 (fr) Utilisation therapeutique de serums d'animaux, en particulier du cheval, pour le traitement du sida, du cancer et d'autres maladies virales et bacteriennes
AU7504096A (en) Pseudomonas exotoxin - myelin basic protein chimeric proteins
EP1354599A3 (fr) Composition pharmaceutique ou alimentaire pour le traitement de pathologies liees a un rejet de greffe
EP0647138A4 (fr) Polypeptides pouvant etre obtenus a partir d'especes de fasciola, et vaccins, procedes de traitement, et sequences d'adn de ces polypeptides.
EP0145486A3 (fr) Procédé microbiologique

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG

AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
COP Corrected version of pamphlet

Free format text: PAGES 1/4-4/4, DRAWINGS, REPLACED BY NEW PAGES 1/4-4/4; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 98500735

Format of ref document f/p: F

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: CA

122 Ep: pct application non-entry in european phase
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载